Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
79K characters. Original on sec.gov ·
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
AND COMPREHENSIVE INCOME
Bio-Techne Corporation and Subsidiaries
(in thousands, except per share data)
(unaudited)
| Quarter Ended December 31, | Six Months Ended December 31, | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Net sales | $ | 269,276 | $ | 224,253 | $ | 526,995 | $ | 428,452 | ||||||||
| Cost of sales | 85,585 | 73,353 | 172,307 | 139,821 | ||||||||||||
| Gross margin | 183,691 | 150,900 | 354,688 | 288,631 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative | 100,693 | 83,116 | 186,868 | 155,714 | ||||||||||||
| Research and development | 20,650 | 16,789 | 42,250 | 32,830 | ||||||||||||
| Total operating expenses | 121,343 | 99,905 | 229,118 | 188,544 | ||||||||||||
| Operating income | 62,348 | 50,995 | 125,570 | 100,087 | ||||||||||||
| Other income (expense) | 23,831 | 5,373 | 27,992 | (4,381 | ) | |||||||||||
| Earnings before income taxes | 86,179 | 56,368 | 153,562 | 95,706 | ||||||||||||
| Income taxes (benefit) | 14,120 | 10,224 | 12,522 | 16,168 | ||||||||||||
| Net earnings, including noncontrolling interest | 72,059 | 46,144 | 141,040 | 79,538 | ||||||||||||
| Net earnings (loss) attributable to noncontrolling interest | (8,114 | ) | (130 | ) | (8,748 | ) | (130 | ) | ||||||||
| Net earnings attributable to Bio-Techne | $ | 80,173 | $ | 46,274 | $ | 149,788 | $ | 79,668 | ||||||||
| Other comprehensive income (loss): | ||||||||||||||||
| Foreign currency translation adjustments | 1,924 | 16,928 | (6,722 | ) | 28,842 | |||||||||||
| Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8 | 2,884 | 2,059 | 4,566 | 4,202 | ||||||||||||
| Other comprehensive income (loss) | 4,808 | 18,987 | (2,156 | ) | 33,044 | |||||||||||
| Other comprehensive income (loss) attributable to noncontrolling interest | 66 | 83 | 27 | 83 | ||||||||||||
| Other comprehensive income (loss) attributable to Bio-Techne | 4,742 | 18,904 | (2,183 | ) | 32,961 | |||||||||||
| Comprehensive income attributable to Bio-Techne | $ | 84,915 | $ | 65,178 | $ | 147,605 | $ | 112,629 | ||||||||
| Earnings per share attributable to Bio-Techne: | ||||||||||||||||
| Basic | $ | 2.04 | $ | 1.20 | $ | 3.82 | $ | 2.06 | ||||||||
| Diluted | $ | 1.94 | $ | 1.15 | $ | 3.64 | $ | 1.98 | ||||||||
| Weighted average common shares outstanding: | ||||||||||||||||
| Basic | 39,310 | 38,691 | 39,202 | 38,614 | ||||||||||||
| Diluted | 41,207 | 40,257 | 41,159 | 40,135 |
See Notes to Condensed Consolidated Financial Statements.
CONDENSED CONSOLIDATED BALANCE SHEETS
Bio-Techne Corporation and Subsidiaries
(in thousands, except share and per share data)
| December 31, 2021 (unaudited) | June 30, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 211,845 | $ | 199,091 | ||||
| Short-term available-for-sale investments | 67,135 | 32,463 | ||||||
| Accounts receivable, less allowance for doubtful accounts of $1,334 and $1,229, respectively | 152,896 | 145,385 | ||||||
| Inventories | 121,858 | 116,748 | ||||||
| Other current assets | 36,496 | 16,919 | ||||||
| Total current assets | 590,230 | 510,606 | ||||||
| Property and equipment, net | 211,814 | 207,907 | ||||||
| Right of use asset | 64,293 | 73,834 | ||||||
| Goodwill | 832,056 | 843,067 | ||||||
| Intangible assets, net | 569,347 | 615,968 | ||||||
| Other assets | 37,106 | 11,575 | ||||||
| Total assets | $ | 2,304,846 | $ | 2,262,957 | ||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Trade accounts payable | $ | 26,756 | $ | 29,384 | ||||
| Salaries, wages and related accruals | 43,921 | 51,294 | ||||||
| Accrued expenses | 18,991 | 15,282 | ||||||
| Contract liabilities | 19,081 | 18,995 | ||||||
| Income taxes payable | 14,284 | 5,336 | ||||||
| Operating lease liabilities - current | 11,809 | 11,602 | ||||||
| Contingent consideration payable | 2,000 | 4,000 | ||||||
| Current portion of long-term debt obligations | 12,500 | 12,500 | ||||||
| Other current liabilities | 5,467 | 3,891 | ||||||
| Total current liabilities | 154,809 | 152,284 | ||||||
| Deferred income taxes | 101,423 | 93,125 | ||||||
| Long-term debt obligations | 269,618 | 328,827 | ||||||
| Long-term contingent consideration payable | 7,000 | 25,400 | ||||||
| Operating lease liabilities | 57,718 | 67,625 | ||||||
| Other long-term liabilities | 11,747 | 24,462 | ||||||
| Bio-Techne's Shareholders' equity: | ||||||||
| Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding | - | - | ||||||
| Common stock, par value $.01 per share; authorized 100,000,000; issued and outstanding 39,319,766 and 38,955,484, respectively | 393 | 390 | ||||||
| Additional paid-in capital | 616,429 | 534,411 | ||||||
| Retained earnings | 1,145,641 | 1,085,461 | ||||||
| Accumulated other comprehensive loss | (59,474 | ) | (57,291 | ) | ||||
| Total Bio-Techne’s shareholders' equity | 1,702,989 | 1,562,971 | ||||||
| Noncontrolling interest | (458 | ) | 8,263 | |||||
| Total shareholders’ equity | 1,702,531 | 1,571,234 | ||||||
| Total liabilities and shareholders’ equity | $ | 2,304,846 | $ | 2,262,957 |
See Notes to Condensed Consolidated Financial Statements.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Bio-Techne Corporation and Subsidiaries
(in thousands)
(unaudited)
| Six Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|
| December 31, | ||||||||
| 2021 | 2020 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net earnings, including noncontrolling interest | $ | 141,040 | $ | 79,538 | ||||
| Adjustments to reconcile net earnings to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 49,836 | 41,972 | ||||||
| Costs recognized on sale of acquired inventory | 1,596 | 23 | ||||||
| Deferred income taxes | 7,233 | 216 | ||||||
| Stock-based compensation expense | 25,706 | 28,531 | ||||||
| Contingent consideration payments | (3,300 | ) | (155 | ) | ||||
| Fair value adjustment to contingent consideration payable | (16,400 | ) | 4,600 | |||||
| Fair value adjustment on available for sale investments | (33,672 | ) | (6,356 | ) | ||||
| Asset impairment restructuring | 546 | - | ||||||
| Eminence impairment | 18,715 | - | ||||||
| Leases, net | (501 | ) | 113 | |||||
| Other operating activity | 383 | 324 | ||||||
| Change in operating assets and operating liabilities, net of acquisition: | ||||||||
| Trade accounts and other receivables, net | (9,347 | ) | (2,327 | ) | ||||
| Inventories | (8,700 | ) | (586 | ) | ||||
| Prepaid expenses | (7,025 | ) | (1,508 | ) | ||||
| Trade accounts payable, accrued expenses, contract liabilities, and other | (175 | ) | 8,624 | |||||
| Salaries, wages and related accruals | (10,408 | ) | (1,713 | ) | ||||
| Income taxes payable | (6,100 | ) | 3,982 | |||||
| Net cash provided by (used in) operating activities | 149,427 | 155,278 | ||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Proceeds from maturities of available-for-sale investments | 12,450 | 43,146 | ||||||
| Purchases of available-for-sale investments | (13,500 | ) | (27,184 | ) | ||||
| Additions to property and equipment | (16,238 | ) | (22,383 | ) | ||||
| Acquisitions, net of cash acquired | - | (9,765 | ) | |||||
| Investment of forward purchase contract | (25,000 | ) | - | |||||
| Other investing activity | - | (556 | ) | |||||
| Net cash provided by (used in) investing activities | (42,288 | ) | (16,742 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Cash dividends | (25,069 | ) | (24,728 | ) | ||||
| Proceeds from stock option exercises | 56,500 | 32,337 | ||||||
| Re-purchases of common stock | (41,294 | ) | - | |||||
| Borrowings under line-of-credit agreement | 50,000 | - | ||||||
| Repayments of long-term debt | (109,250 | ) | (125,250 | ) | ||||
| Contingent consideration payments | (700 | ) | - | |||||
| Other financing activity | (23,247 | ) | (7,371 | ) | ||||
| Net cash provided by (used in) financing activities | (93,060 | ) | (125,012 | ) | ||||
| Effect of exchange rate changes on cash and cash equivalents | (1,325 | ) | 5,377 | |||||
| Net change in cash and cash equivalents | 12,754 | 18,901 | ||||||
| Cash and cash equivalents at beginning of period | 199,091 | 146,625 | ||||||
| Cash and cash equivalents at end of period | $ | 211,845 | $ | 165,526 | ||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid for income taxes | $ | 15,368 | $ | 11,007 | ||||
| Cash paid for interest | $ | 6,144 | $ | 7,779 |
See Notes to Condensed Consolidated Financial Statements.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Bio-Techne Corporation and Subsidiaries
(unaudited)
Note 1. Basis of Presentation and Summary of Significant Accounting Policies:
The interim consolidated financial statements of Bio-Techne Corporation and subsidiaries, (the Company) presented here have been prepared by the Company and are unaudited. They have been prepared in accordance with accounting principles generally accepted in the United States of America and with instructions to Form 10-Q and Article 10 of Regulation S-X. They reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. All such adjustments are of a normal recurring nature.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These interim unaudited condensed consolidated financial statements should be read in conjunction with the Company's Consolidated Financial Statements and Notes thereto for the fiscal year ended June 30, 2021, included in the Company's Annual Report on Form 10-K for fiscal 2021. A summary of significant accounting policies followed by the Company is detailed in the Company's Annual Report on Form 10-K for fiscal 2021. The Company follows these policies in preparation of the interim unaudited condensed consolidated financial statements.
During the six months ended December 31, 2021, the Company operated under two operating segments, Protein Sciences and Diagnostics and Genomics. The operating segments the Company operated under were consistent with the Company's operating segments disclosed in the Company's Annual Report on Form 10-K for fiscal 2021.
Goodwill: In the second quarter of fiscal 2022, Changzhou Eminence Biotechnology Co., Ltd. (Eminence) notified the Company of its need for additional capital to execute its growth plan. The Company first attempted to find outside equity financing support for the Eminence investment but was unable to do so. The Company then reviewed the additional financing needs required to successfully ramp Eminence’s business, which ultimately did not meet the Company’s return on capital requirements. Therefore, the Company did not provide additional funding to Eminence. As a result of not obtaining additional financing, Eminence notified the Company of its plans to cease operations and liquidate its business.
Given the upcoming liquidation process to dispose of the Eminence assets, the Company identified a triggering event in the second quarter of fiscal 2022 and performed impairment testing. The impairment testing resulted in a full impairment of the Eminence goodwill and intangible assets, which resulted in charges of $8.3 million and $8.6 million, respectively. The Company also recognized inventory and fixed asset impairment charges of $0.9 million and $0.9 million, respectively.
The Company recorded the impairment charges within the General and Administrative line in the Consolidated Income Statement. The impact on net income attributable to Bio-Techne was approximately $8 million, after taking into effect non-controlling interest holders. The remaining net tangible assets of Eminence included in our Consolidated Balance Sheet were approximately $4 million and primarily consisted of fixed assets and related deposits of $3.7 million, inventory of $0.9 million, receivables of $0.6 million, and other current assets of $0.2 million. The Company also had $1.6 million related to current liabilities. The Company holds a financial interest of approximately 57.4% in those tangible assets in the liquidation process.
Investments: In December 2021, the Company paid $25 million to enter into a two-part forward contract which requires the Company to make an initial ownership investment followed by purchase of full equity interest in Wilson Wolf Corporation (Wilson Wolf) if certain annual revenue or EBITDA thresholds are met. Wilson Wolf is a leading manufacturer of cell culture devices, including the G-Rex product line.
The first part of the forward contract is triggered upon Wilson Wolf achieving approximately $92 million in annual revenue or $55 million in annual earnings before interest, taxes, depreciation, and amortization (EBITDA) at any point prior to December 31, 2027. Once triggered, the Company is required to make an additional investment of $231 million in exchange for a 19.9% ownership stake. If Wilson Wolf doesn’t achieve the revenue and EBITDA targets by December 31, 2027, the agreement will expire.
Once the first part of the forward contract is triggered, the second part of the forward contract will automatically trigger, and requires the Company to acquire the remaining equity interest in Wilson Wolf on December 31, 2027 based on a revenue multiple. The second part of the contract would be accelerated in advance of December 31, 2027, if Wilson Wolf meets its second milestone of approximately $226 million in annual revenue or $136 million in annual EBITDA. If the second milestone is achieved, the forward contract requires the Company to pay approximately $1 billion plus potential consideration for revenue in excess of the revenue milestone. The approximate multiple for total expected payments of the second forward contract is 4.4 times the annual revenue of Wilson Wolf. The Company has elected to apply the measurement alternative as detailed under ASC 321-10-35-2 for the Wilson Wolf investment. The Company recorded the $25 million payment as a cost basis investment within Other long-term assets on the Consolidated Balance Sheet.
4
Restructuring actions: Restructuring actions generally include significant actions involving employee-related severance charges, contract termination costs, and impairments and disposals of assets associated with such actions. Employee-related severance charges are based upon distributed employment policies and substantive severance plans. These charges are reflected in the quarter when the actions are probable and the amounts are estimable, which typically is when management approves the associated actions. Asset impairment and disposal charges include right of use assets, leasehold improvements, and other asset write-downs associated with combining operations and disposal of assets.
In September 2021, the Company informed employees of our decision to close our Exosome Diagnostics Germany facility, discontinuing lab and research occurring at the site, as part of a realignment of activities within our Exosome Diagnostics business. The closure of the site is expected to be completed in the third quarter of fiscal 2022. As a result of the restructuring activities, an estimated pre-tax charge of $1.2 million was recorded within our Diagnostics and Genomics segment during the first quarter of fiscal 2022. Additional charges of approximately $0.5 million were recorded in the quarter ended December 31, 2021. These additional charges related to the refinement of our estimated close down costs as well as miscellaneous shut-down costs incurred during the quarter. Total restructuring charges for the closure of the Exosome Diagnostics Germany facility for the six months ended December 31, 2021 were recorded within operating income on the income statement as follows (in thousands):
| Employee Severance | Asset Impairment and other | Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, general and administrative | $ | 940 | $ | 750 | $ | 1,690 |
Restructuring actions, including cash and non-cash impacts, are as follows (in thousands):
| Employee Severance | Other | Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accrued restructuring action balances as of September 31, 2021(1) | $ | 639 | $ | 364 | $ | 1,003 | ||||||
| Incremental expense incurred in the second quarter of fiscal 2022 | - | 242 | 242 | |||||||||
| Cash payments | (370 | ) | (242 | ) | (612 | ) | ||||||
| Adjustments | 301 | (37 | ) | 264 | ||||||||
| Accrued restructuring actions balances as of December 31, 2021 | $ | 570 | $ | 327 | $ | 897 |
(1) The expense recorded for the three months ended September 31, 2021 of $1.2 million included $0.2 million related to the non-cash impairment of fixed assets.
During the second quarter of fiscal 2022, the Company also incurred a restructuring charge of $0.2 million related to employee severance for the relocation of a US plant. This charge is recorded within Other current liabilities as of December 31, 2021. There were no cash payments related to this restructuring during the period ended December 31, 2021.
Recently Adopted Accounting Pronouncements
There were no accounting pronouncements adopted in the first and second quarter of fiscal 2022. Refer to the Form 10-K for accounting pronouncements adopted prior to June 30, 2021.
Note 2. Revenue Recognition:
Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues consist of extended warranty contracts, post contract support, and custom development projects that are recognized over time as either the customers receive and consume the benefits of such services simultaneously or the underlying asset being developed has no alternative use for the Company at contract inception and the Company has an enforceable right to payment for the portion of the performance completed. Service revenues also include laboratory services recognized at point in time. Prior to fiscal 2021, the Company has not recognized revenue upon completion of the performance obligation for laboratory services, but rather upon cash receipt, which was subsequent to the performance obligation being satisfied. The Company accounted for these services based on cash receipts as we did not have significant historical experience collecting payments from Medicare or other insurance providers and considered the variable consideration for such services to be constrained as it would not be probable that a significant amount of revenue would not need to be reversed in future periods for the services provided. Given Medicare coverage for our laboratory services became effective on December 1, 2019, the Company considered it to have sufficient data to estimate variable consideration as of July 1, 2020 for laboratory services that are reimbursed by Medicare. The amount of cash received in fiscal 2021 for laboratory services reimbursed by Medicare that were performed prior to July 1, 2020 was approximately $0.5 million. The Company continues to record revenue based on cash receipts for laboratory services not reimbursed by Medicare, as the variable consideration remains constrained. We recognize royalty revenues in the period the sales occur using third party evidence. The Company elected the "right to invoice" practical expedient based on the Company's right to invoice a customer at an amount that approximates the value to the customer and the performance completed to date.
The Company elected the exemption to not disclose the unfulfilled performance obligations for contracts with an original length of one year or less and the exemption to exclude future performance obligations that are accounted under the sales-based or usage-based royalty guidance. The Company’s unfulfilled performance obligations were not material as of December 31, 2021.
Contracts with customers that contain instruments may include multiple performance obligations. For these contracts, the Company allocates the contract’s transaction price to each performance obligation on a relative standalone selling price basis. Allocation of the transaction price is determined at the contracts’ inception.
Payment terms for shipments to end-users are generally net 30 days. Payment terms for distributor shipments may range from 30 to 90 days. Service arrangements commonly call for payments in advance of performing the work (e.g. extended warranty and service contracts), upon completion of the service (e.g. custom development manufacturing) or a mix of both.
Contract assets include revenues recognized in advance of billings. Contract assets are included within other current assets in the accompanying balance sheet as the amount of time expected to lapse until the company's right to consideration becomes unconditional is less than one year. We elected the practical expedient allowing us to expense contract costs that would otherwise be capitalized and amortized over a period of less than one year. Contract assets as of December 31, 2021 are not material.
Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on warranty contracts. Contract liabilities as of December 31, 2021 and June 30, 2021 were approximately $20.8 million and $20.0 million, respectively. Contract liabilities as of June 30, 2021 subsequently recognized as revenue during the quarter and six month period ended December 31, 2021 were approximately $3.6 million and $13.3 million, respectively. Contract liabilities in excess of one year are included in Other long-term liabilities on the consolidated balance sheet.
Any claims for credit or return of goods must be made within 10 days of receipt. Revenues are reduced to reflect estimated credits and returns. Although the amounts recorded for these revenue deductions are dependent on estimates and assumptions, historically our adjustments to actual results have not been material.
Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. We elected the practical expedient that allows us to account for shipping and handling activities that occur after the customer has obtained control of a good as a fulfillment cost, and we accrue costs of shipping and handling when the related revenue is recognized.
The following tables present our disaggregated revenue for the periods presented.
Revenue by type is as follows:
| Quarter Ended | Six Months Ended | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| December 31, | December 31, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Consumables | $ | 212,706 | $ | 177,464 | $ | 418,397 | $ | 344,091 | ||||||||
| Instruments | 33,353 | 26,529 | 63,222 | 46,101 | ||||||||||||
| Services | 17,354 | 15,175 | 33,611 | 30,639 | ||||||||||||
| Total product and services revenue, net | $ | 263,413 | $ | 219,168 | $ | 515,230 | $ | 420,831 | ||||||||
| Royalty revenues | 5,863 | 5,085 | 11,765 | 7,621 | ||||||||||||
| Total revenues, net | $ | 269,276 | $ | 224,253 | $ | 526,995 | $ | 428,452 |
Revenue by geography is as follows:
| Quarter Ended | Six Months Ended | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| December 31, | December 31, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| United States | $ | 142,367 | $ | 114,439 | $ | 283,069 | $ | 228,001 | ||||||||
| EMEA, excluding United Kingdom | 57,159 | 49,936 | 108,702 | 93,070 | ||||||||||||
| United Kingdom | 11,842 | 9,852 | 24,320 | 18,386 | ||||||||||||
| APAC, excluding Greater China | 19,603 | 18,008 | 37,104 | 33,742 | ||||||||||||
| Greater China | 31,009 | 25,165 | 59,442 | 43,218 | ||||||||||||
| Rest of World | 7,296 | 6,853 | 14,358 | 12,035 | ||||||||||||
| Net Sales | $ | 269,276 | $ | 224,253 | $ | 526,995 | $ | 428,452 |
Note 3. Selected Balance Sheet Data:
Inventories:
Inventories consist of (in thousands):
| December 31, | June 30, | |||||||
|---|---|---|---|---|---|---|---|---|
| 2021 | 2021 | |||||||
| Raw materials | $ | 61,624 | $ | 55,096 | ||||
| Finished goods(1) | 65,620 | 67,108 | ||||||
| Inventories, net | $ | 127,244 | $ | 122,204 |
(1)Finished goods inventory of $5,386 and $5,456 included within other long-term assets in the respective December 31, 2021 and June 30, 2021, consolidated balance sheet. The inventory is included in long-term assets as it is forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.
Property and Equipment:
Property and equipment consist of (in thousands):
| December 31, | June 30, | |||||||
|---|---|---|---|---|---|---|---|---|
| 2021 | 2021 | |||||||
| Land | $ | 8,587 | $ | 8,612 | ||||
| Buildings and improvements | 225,501 | 190,661 | ||||||
| Machinery and equipment | 161,431 | 149,410 | ||||||
| Construction in progress | 17,386 | 49,073 | ||||||
| Property and equipment, cost | 412,905 | 397,756 | ||||||
| Accumulated depreciation and amortization | (201,091 | ) | (189,849 | ) | ||||
| Property and equipment, net | $ | 211,814 | $ | 207,907 |
Intangible Assets:
Intangible assets consist of (in thousands):
| December 31, | June 30, | |||||||
|---|---|---|---|---|---|---|---|---|
| 2021 | 2021 | |||||||
| Developed technology | $ | 544,388 | $ | 552,160 | ||||
| Trade names | 147,327 | 147,640 | ||||||
| Customer relationships | 228,419 | 232,493 | ||||||
| Patents | 3,116 | 2,926 | ||||||
| Other intangibles | 6,309 | 6,316 | ||||||
| Definite-lived intangible assets | 929,559 | 941,535 | ||||||
| Accumulated amortization | (382,912 | ) | (348,267 | ) | ||||
| Definite-lived intangibles assets, net | 546,647 | 593,268 | ||||||
| In process research and development | 22,700 | 22,700 | ||||||
| Total intangible assets, net | $ | 569,347 | $ | 615,968 |
7
Changes to the carrying amount of net intangible assets for the quarter ended December 31, 2021 consist of (in thousands):
| Beginning balance | $ | 615,968 | ||
|---|---|---|---|---|
| Acquisitions | - | |||
| Other additions | 171 | |||
| Amortization expense | (37,258 | ) | ||
| Currency translation | (971 | ) | ||
| Eminence impairment (1) | (8,563 | ) | ||
| Ending balance | $ | 569,347 |
The estimated future amortization expense for intangible assets as of December 31, 2021 is as follows (in thousands):
| 2022 remainder | $ | 36,927 | ||
|---|---|---|---|---|
| 2023 | 71,669 | |||
| 2024 | 68,818 | |||
| 2025 | 65,579 | |||
| 2026 | 61,819 | |||
| Thereafter | 241,835 | |||
| Total | $ | 546,647 |
(1)As disclosed in Note 1, the Company recorded an impairment charge of $8.6 million related to Eminence in Q2 of FY'22.
Goodwill:
Changes to the carrying amount of goodwill for the quarter ended December 31, 2021 consist of (in thousands):
| Protein Sciences | Diagnostics and Genomics | Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beginning balance | $ | 392,717 | $ | 450,350 | $ | 843,067 | ||||||
| Acquisitions | - | - | - | |||||||||
| Eminence impairment | (8,275 | ) | - | (8,275 | ) | |||||||
| Currency translation | (2,610 | ) | (126 | ) | (2,736 | ) | ||||||
| Ending balance | $ | 381,832 | $ | 450,224 | $ | 832,056 |
We evaluate the carrying value of goodwill in the fourth quarter of each fiscal year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. The Company performed a quantitative goodwill impairment assessment for all of its reporting units during the fourth quarter of fiscal 2021. No indicators of impairment were identified as part of our assessment.
During the quarter ended September 30, 2021, the Company combined the management of the Exosome Diagnostics and Asuragen reporting units, both of which are included in the Diagnostics and Genomics operating segment. In conjunction with the combination of the reporting units, a qualitative goodwill impairment assessment was performed. The qualitative assessment identified no indicators of impairment.
As disclosed in Note 1, the Company identified a triggering event and a goodwill impairment charge of $8.3 million in the quarter ended December 31, 2021. No additional triggering events or items beyond the upcoming Eminence liquidation were identified during the quarter ended December 31, 2021. The impairment of the Eminence goodwill is the only impairment of goodwill recorded since the adoption of Financial Accounting Standards Board ("FASB") ASC 350 guidance for goodwill and other intangibles on July 1, 2002.
Note 4. Acquisitions:
We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and that the results of operations of each acquired business be included in our consolidated statements of comprehensive income from their respective dates of acquisitions. Acquisition costs are recorded in selling, general and administrative expenses as incurred.
2021 Acquisitions
Asuragen, Inc.
On April 6, 2021, the Company acquired all of the ownership interests of Asuragen, Inc. (Asuragen) for approximately $216 million, net of cash acquired, plus contingent consideration of up to $105.0 million, subject to certain revenue thresholds. The Asuragen acquisition adds a leading portfolio of best in-class molecular diagnostic and research products, including genetic screening, oncology testing kits, molecular controls, a GMP compliant manufacturing facility, and a CLIA-certified laboratory. The transaction was accounted for in accordance with ASC 805, Business Combinations. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’ product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Diagnostics and Genomics operating segment in the fourth quarter of fiscal 2021.
Purchase accounting remained open as of December 31, 2021 for our income tax assessment of acquired net operating losses with the completion of the stub period tax returns and the corresponding goodwill impact. The Company expects to finalize the allocation of purchase price in the third quarter of fiscal 2022. Net sales and operating loss of this business included in Bio-Techne's consolidated results of operations for the quarter ended December 31, 2021 were approximately $8.8 million and $0.4 million, respectively. Net sales and operating loss of this business included in Bio-Techne's consolidated results of operations for the six months ended December 31, 2021 were approximately $16.4 million and $3.6 million, respectively. The preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date and at December 31, 2021 are as follows (in thousands):
| Preliminary allocation at acquisition date and at December 31, 2021 | ||||
|---|---|---|---|---|
| Current assets, net of cash | $ | 10,422 | ||
| Equipment and other long-term assets | 3,762 | |||
| Intangible assets: | ||||
| Developed technology | 107,000 | |||
| In-process research and development | 22,700 | |||
| Customer relationships | 11,700 | |||
| Trade names | 2,000 | |||
| Non-competition agreement | 1,000 | |||
| Goodwill | 94,970 | |||
| Total assets acquired | 253,554 | |||
| Liabilities | 4,003 | |||
| Deferred income taxes, net | 15,664 | |||
| Net assets acquired | $ | 233,887 | ||
| Cash paid, net of cash acquired | 215,587 | |||
| Contingent consideration payable | 18,300 | |||
| Net assets acquired | $ | 233,887 |
Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's preliminary assessment. The purchase price allocated to developed technology, in-process research and development, and customer relationships was based on management's preliminary forecasted cash inflows and outflows and using a multiperiod excess earnings method to calculate the fair value of assets purchased. The amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for developed technology is estimated to be 14 years. Amortization expense related to customer relationships is reflected in selling, general and administrative expenses in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships is estimated to be 16 years. The amount recorded for trade names and the non-competition agreement is being amortized with the expense reflected in selling, general and administrative expenses in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for trade names and the non-competition agreement is estimated to be 5 years and 3 years, respectively. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes, offset by the deferred tax asset for the preliminary calculation of acquired net operating losses.
Note 5. Fair Value Measurements:
The Company’s financial instruments include cash and cash equivalents, available for sale investments, derivative instruments, accounts receivable, accounts payable, contingent consideration obligations, and long-term debt.
Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances.
The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels. Level 1 inputs are quoted prices in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable for the asset or liability and their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Level 3 may also include certain investment securities for which there is limited market activity or a decrease in the observability of market pricing for the investments, such that the determination of fair value requires significant judgment or estimation.
The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands):
| Total carrying value as of | Fair Value Measurements Using Inputs Considered as | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| December 31, 2021 | Level 1 | Level 2 | Level 3 | |||||||||||||
| Assets | ||||||||||||||||
| Equity securities (1) | $ | 53,635 | $ | 50,525 | $ | 3,110 | $ | - | ||||||||
| Certificates of deposit (2) | 13,500 | 13,500 | - | - | ||||||||||||
| Derivative instruments – cash flow hedges | 2,254 | - | 2,254 | - | ||||||||||||
| Total assets | $ | 69,389 | $ | 64,025 | $ | 5,364 | $ | - | ||||||||
| Liabilities | ||||||||||||||||
| Contingent consideration | $ | 9,000 | $ | - | $ | - | $ | 9,000 | ||||||||
| Derivative instruments - cash flow hedges | 4,382 | - | 4,382 | - | ||||||||||||
| Total liabilities | $ | 13,382 | $ | - | $ | 4,382 | $ | 9,000 |
| Total carrying value as of | Fair Value Measurements Using Inputs Considered as | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 30, 2021 | Level 1 | Level 2 | Level 3 | |||||||||||||
| Assets | ||||||||||||||||
| Equity securities (1) | $ | 19,963 | $ | 18,581 | $ | 1,382 | $ | - | ||||||||
| Certificates of deposit (2) | 12,500 | 12,500 | - | - | ||||||||||||
| Derivative instruments – cash flow hedges | 275 | - | 275 | - | ||||||||||||
| Total assets | $ | 32,738 | $ | 31,081 | $ | 1,657 | $ | - | ||||||||
| Liabilities | ||||||||||||||||
| Contingent consideration | $ | 29,400 | $ | - | $ | - | $ | 29,400 | ||||||||
| Derivative instruments - cash flow hedges | 8,376 | - | 8,376 | - | ||||||||||||
| Total liabilities | $ | 37,776 | $ | - | $ | 8,376 | $ | 29,400 |
| (1) | Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in ChemoCentryx Inc (CCXI) was $6.6 million at both December 31, 2021 and June 30, 2021. The Company has a warrant to purchase additional CCXI equity shares which was valued at $3.1 million and $1.4 million as of December 31, 2021 and June 30, 2021, respectively. |
|---|---|
| (2) | Included in available-for-sale investments on the balance sheet. The certificates of deposit have contractual maturity dates within one year. |
10
Fair value measurements of available for sale securities
Our available for sale securities are measured at fair value using quoted market prices in active markets for identical assets and are therefore classified as Level 1 assets. The Company's warrant to purchase additional shares at a specified future price was valued using a Black-Scholes model with observable inputs in active markets and therefore was classified as a Level 2 asset.
Fair value measurements of derivative instruments
In October 2018, the Company entered into forward starting swaps designated as cash flow hedges on outstanding debt. The forward starting swaps reduce the variability of cash flow payments for the Company by converting the variable interest rate on the Company’s long-term debt described in Note 6 to that of a fixed interest rate. Accordingly, as part of the forward starting swaps, the Company exchanges, at specified intervals, the difference between floating and fixed interest amounts based on an initial $380 million of notional principal amount. The notional amount decreased by $100 million in October 2020, $80 million in October 2021 and will further decrease by $200 million in October 2022. In June 2020, the Company de-designated $80 million of the notional amount set to expire in October 2020. The net loss associated with the June 2020 de-designated portion of the derivative instrument was not reclassified into earnings based on the amount of probable variable interest payments to occur within a two-month time period of the forecasted hedged transaction. In December 2020, the Company de-designated an additional $80 million of notional amount set to expire in October 2021. The net loss associated with the December 2020 de-designated portion of the derivative instrument was recorded as a loss in other non-operating income related to variable interest debt payments in certain months on a portion of the de-designated derivative that was not expected to occur. The fair value of the designated derivative instrument is $4.4 million and is recorded within short-term liabilities on the Consolidated Balance Sheet as of December 31, 2021. The fair value of the designated derivative instrument was $7.6 million as of June 30, 2021 and was recorded within other long-term liabilities on the Consolidated Balance Sheet.
In May 2021, the Company entered into a new forward starting swap designated as a cash flow hedge on forecasted debt. The forward starting swap reduces the variability of cash flow payments for the Company by converting the variable interest rate on the Company’s forecasted variable interest long-term debt to that of a fixed interest rate. Accordingly, as part of the forward starting swap, the Company exchanges, at specified intervals, the difference between floating and fixed interest amounts based on $200 million of notional principal amount. The effective date of the swap is November 2022 with the full swap maturing in November 2025. The fair value of the derivative instrument was $2.3 million and $0.3 million as of December 31, 2021 and June 30, 2021, respectively, which is recorded within other long-term assets on the Consolidated Balance Sheet.
Changes in the fair value of the designated hedged instruments are reported as a component of other comprehensive income and reclassified into interest expense over the corresponding term of the cash flow hedge. The Company reclassified $3.8 million to interest expense and related tax benefits of $0.9 million during the six months ended December 31, 2021. The Company reclassified $5.0 million to interest expense, $0.5 million to non-operating income for the portion of de-designated variable payments considered probable to not occur, and related tax benefits of $1.3 million during the six months ended December 31, 2020.The instruments were valued using observable market inputs in active markets and therefore are classified as Level 2 liabilities.
Fair value measurements of contingent consideration
The Company has $9 million in contingent consideration recorded as of December 31, 2021, which is the fair value of contingent consideration related to the Asuragen and B-MoGen Biotechnologies Inc ("B-MoGen") acquisitions. The Company is required to make contingent consideration payments of up to $105.0 million and $38.0 million, respectively, as part of these acquisition agreements. The contingent agreement for Asuragen is based on achieving certain revenue thresholds. The opening balance sheet fair value of the liabilities for the Asuragen acquisition was $18.3 million, as discussed in Note 4. The contingent agreement for B-MoGen is based on meeting certain product development milestones and revenue thresholds. The fair value amount recorded on the opening balance sheet of the revenue milestone payments was determined using a Monte Carlo simulation-based model discounted to present value. Assumptions used in these calculations are units sold, expected revenue, expected expenses, discount rate, and various probability factors.
The ultimate settlement of contingent consideration liabilities for the Asuragen and B-Mogen acquisitions could deviate from current estimates based on the actual results of the financial measures described above. This liability is considered to be a Level 3 financial liability that is re-measured each reporting period. The change in fair value of contingent consideration for these acquisitions is included in general and administrative expense.
During the first quarter of fiscal 2022_,_ the Company made a $4.0 million payment on the QT Holdings Corporation contingent consideration agreement relating to certain product development milestones. The cash paid was consistent with the related accrual as of June 30, 2021_._
The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):
| Quarter Ended | Six Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|
| December 31, 2021 | December 31, 2021 | |||||||
| Fair value at the beginning of period | $ | 22,600 | $ | 29,400 | ||||
| Change in fair value of contingent consideration | (13,600 | ) | (16,400 | ) | ||||
| Payments | - | (4,000 | ) | |||||
| Fair value at the end of period | $ | 9,000 | $ | 9,000 |
The use of different assumptions, applying different judgment to matters that inherently are subjective and changes in future market conditions could result in different estimates of fair value of our securities or contingent consideration, currently and in the future. If market conditions deteriorate, we may incur impairment charges for securities in our investment portfolio.
Fair value measurements of other financial instruments – The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practicable to estimate fair value.
Cash and cash equivalents, certificates of deposit, accounts receivable, and accounts payable – The carrying amounts reported in the consolidated balance sheets approximate fair value because of the short-term nature of these items.
Long-term debt – The carrying amounts reported in the consolidated balance sheets for the amount drawn on our line-of-credit facility and long-term debt approximates fair value because our interest rate is variable and reflects current market rates.
Note 6. Debt and Other Financing Arrangements:
On August 1, 2018, the Company entered into a new revolving line-of-credit and term loan governed by a Credit Agreement (the Credit Agreement). The Credit Agreement provides for a revolving credit facility of $600.0 million, which can be increased by an additional $200.0 million subject to certain conditions, and a term loan of $250.0 million. Borrowings under the Credit Agreement may be used for working capital and expenditures of the Company and its subsidiaries, including financing permitted acquisitions. Borrowings under the Credit Agreement bear interest at a variable rate. The current outstanding debt is based on the Eurodollar Loans term for which the interest rate is calculated as the sum of LIBOR plus an applicable margin. The applicable margin is determined from the total leverage ratio of the Company and updated on a quarterly basis. The annualized fee for any unused portion of the credit facility is currently 12.5 basis points.
The Credit Agreement matures on August 1, 2023 and contains customary restrictive and financial covenants and customary events of default. As of December 31, 2021, the outstanding balance under the Credit Agreement was $282.3 million.
Note 7. Leases:
As a lessee, the company leases offices, labs, and manufacturing facilities, as well as vehicles, copiers, and other equipment. The Company adopted ASU No. 2016-02 and related standards (collectively ASC 842, Leases), which replaced previous lease accounting guidance, on July 1, 2019.
The Company recognizes operating lease expense on a straight-line basis over the lease term. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to calculate present value is Bio-Techne’s incremental borrowing rate or, if available, the rate implicit in the lease. Bio-Techne determines the incremental borrowing rate for each lease based primarily on its lease term and the economic environment of the applicable country or region. During the six months ended December 31, 2021, the Company recognized $2.1 million in variable lease expense and $7.3 million relating to fixed lease expense in the Condensed Consolidated Statements of Earnings and Comprehensive Income.
The following table summarizes the balance sheet classification of the Company’s operating leases and amounts of right of use assets and lease liabilities and the weighted average remaining lease term and weighted average discount rate for the Company’s operating leases (asset and liability amounts are in thousands):
| Balance Sheet Classification | As of: December 31, 2021 | ||||
|---|---|---|---|---|---|
| Operating leases: | |||||
| Operating lease right of use assets | Right of Use Asset | $ | 64,293 | ||
| Current operating lease liabilities | Operating lease liabilities current | $ | 11,809 | ||
| Noncurrent operating lease liabilities | Operating lease liabilities | 57,718 | |||
| Total operating lease liabilities | $ | 69,527 | |||
| Weighted average remaining lease term (in years): | 7.25 | ||||
| Weighted average discount rate: | 3.87 | % |
The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities for the six months ended (in thousands):
| Six months ended December 31, 2021 | ||||
|---|---|---|---|---|
| Cash amounts paid on operating lease liabilities | $ | 7,504 | ||
| Right of use assets obtained in exchange for lease liabilities | 575 |
The following table summarizes the fair value of the lease liability by payment date for the Company’s operating leases by fiscal year (in thousands):
| Operating Leases | ||||
|---|---|---|---|---|
| Remainder of fiscal 2022 | $ | 7,176 | ||
| 2023 | 13,191 | |||
| 2024 | 11,511 | |||
| 2025 | 10,353 | |||
| 2026 | 9,628 | |||
| Thereafter | 27,902 | |||
| Total | $ | 79,761 | ||
| Less: Amounts representing interest | 10,234 | |||
| Total Lease obligations | $ | 69,527 |
Certain leases include one or more options to renew, with terms that extend the lease term up to five years. Bio-Techne includes the option to renew the lease as part of the right of use lease asset and liability when it is reasonably certain the Company will exercise the option. In addition, certain leases contain fair value purchase and termination options with an associated penalty. In general, Bio-Techne is not reasonably certain to exercise such options.
_Note _8.__ Supplemental Equity and Accumulated Other Comprehensive Income (Loss):
Supplemental Equity
The Company has declared cash dividends per share of $0.32 and $0.64 in both the three and six months ended December 31, 2021 and 2020, respectively.
Consolidated Changes in Equity (amounts in thousands)
| Bio-Techne Shareholders | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accumulated | ||||||||||||||||||||||||||||
| Additional | Other | |||||||||||||||||||||||||||
| Common Stock | Paid-in | Retained | Comprehensive | Noncontrolling | ||||||||||||||||||||||||
| Shares | Amount | Capital | Earnings | Income(Loss) | Interest | Total | ||||||||||||||||||||||
| Balances at June 30, 2021 | 38,955 | $ | 390 | $ | 534,411 | $ | 1,085,461 | $ | (57,291 | ) | $ | 8,263 | $ | 1,571,234 | ||||||||||||||
| Net earnings | 69,615 | (634 | ) | 68,981 | ||||||||||||||||||||||||
| Other comprehensive income (loss) | (6,925 | ) | (39 | ) | (6,964 | ) | ||||||||||||||||||||||
| Share repurchases | ||||||||||||||||||||||||||||
| Common stock issued for exercise of options | 295 | 3 | 36,345 | (13,481 | ) | 22,867 | ||||||||||||||||||||||
| Common stock issued for restricted stock awards | 20 | 0 | 0 | (9,765 | ) | (9,765 | ) | |||||||||||||||||||||
| Cash dividends | (12,493 | ) | (12,493 | ) | ||||||||||||||||||||||||
| Stock-based compensation expense | 11,396 | 11,396 | ||||||||||||||||||||||||||
| Common stock issued to employee stock purchase plan | 3 | 0 | 1,358 | 1,358 | ||||||||||||||||||||||||
| Employee stock purchase plan expense | 341 | 341 | ||||||||||||||||||||||||||
| Balances at September 30, 2021 | 39,273 | $ | 393 | $ | 583,851 | $ | 1,119,337 | $ | (64,216 | ) | $ | 7,590 | $ | 1,646,955 | ||||||||||||||
| Net earnings | 80,173 | (8,114 | ) | 72,059 | ||||||||||||||||||||||||
| Other comprehensive income (loss) | 4,742 | 66 | 4,808 | |||||||||||||||||||||||||
| Share repurchases | (89 | ) | (1 | ) | (41,293 | ) | (41,294 | ) | ||||||||||||||||||||
| Common stock issued for exercise of options | 134 | 1 | 18,604 | 18,605 | ||||||||||||||||||||||||
| Common stock issued for restricted stock awards | 1 | |||||||||||||||||||||||||||
| Cash dividends | (12,576 | ) | (12,576 | ) | ||||||||||||||||||||||||
| Stock-based compensation expense | 13,701 | 13,701 | ||||||||||||||||||||||||||
| Common stock issued to employee stock purchase plan | 6 | 6 | ||||||||||||||||||||||||||
| Employee stock purchase plan expense | 267 | 267 | ||||||||||||||||||||||||||
| Balances at December 31, 2021 | 39,319 | 393 | 616,429 | 1,145,641 | (59,474 | ) | (458 | ) | 1,702,531 |
| Bio-Techne Shareholders | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accumulated | ||||||||||||||||||||||||||||
| Additional | Other | |||||||||||||||||||||||||||
| Common Stock | Paid-in | Retained | Comprehensive | Noncontrolling | ||||||||||||||||||||||||
| Shares | Amount | Capital | Earnings | Income(Loss) | Interest | Total | ||||||||||||||||||||||
| Balances at June 30, 2020 | 38,453 | $ | 385 | $ | 420,536 | $ | 1,057,470 | $ | (97,199 | ) | $ | - | $ | 1,381,192 | ||||||||||||||
| Cumulative effect adjustments due to adoption of new accounting standards | (276 | ) | (276 | ) | ||||||||||||||||||||||||
| Net earnings | 33,395 | 33,395 | ||||||||||||||||||||||||||
| Other comprehensive income (loss) | 14,057 | 14,057 | ||||||||||||||||||||||||||
| Common stock issued for exercise of options | 117 | 1 | 13,727 | 13,728 | ||||||||||||||||||||||||
| Common stock issued for restricted stock awards | 25 | 0 | (0 | ) | (4,890 | ) | (4,890 | ) | ||||||||||||||||||||
| Cash dividends | (12,336 | ) | (12,336 | ) | ||||||||||||||||||||||||
| Stock-based compensation expense | 12,667 | 12,667 | ||||||||||||||||||||||||||
| Common stock issued to employee stock purchase plan | 6 | 0 | 1,463 | 1,463 | ||||||||||||||||||||||||
| Employee stock purchase plan expense | 286 | 286 | ||||||||||||||||||||||||||
| Balances at September 30, 2020 | 38,601 | $ | 386 | $ | 448,679 | $ | 1,073,362 | $ | (83,142 | ) | $ | - | $ | 1,439,285 | ||||||||||||||
| Non-controlling interest in Eminence | 8,985 | 8,985 | ||||||||||||||||||||||||||
| Net earnings | 46,274 | (130 | ) | 46,144 | ||||||||||||||||||||||||
| Other comprehensive income (loss) | 18,904 | 83 | 18,987 | |||||||||||||||||||||||||
| Common stock issued for exercise of options | 161 | 2 | 16,748 | (2,482 | ) | 14,268 | ||||||||||||||||||||||
| Common stock issued for restricted stock awards | 3 | 0 | (0 | ) | 0 | 0 | ||||||||||||||||||||||
| Cash dividends | (12,392 | ) | (12,392 | ) | ||||||||||||||||||||||||
| Stock-based compensation expense | 15,471 | 15,471 | ||||||||||||||||||||||||||
| Employee stock purchase plan expense | 106 | 106 | ||||||||||||||||||||||||||
| Balances at December 31, 2020 | 38,765 | $ | 388 | $ | 481,004 | $ | 1,104,762 | $ | (64,238 | ) | $ | 8,938 | $ | 1,530,854 |
13
Accumulated Other Comprehensive Income
The components of other comprehensive income (loss) consist of changes in foreign currency translation adjustments and changes in net unrealized gains (losses) on derivative instruments designated as cash flow hedges. The Company reclassified $2.9 million, net of taxes, from accumulated other comprehensive income (loss) to earnings during the six months ended December 31, 2021. The Company reclassified $4.2 million, net of taxes, from accumulated other comprehensive income (loss) to earnings during the six months ended December 31, 2020.
The accumulated balances related to each component of other comprehensive income (loss) attributable to Bio-Techne, net of tax, are summarized as follows:
| Unrealized Gains (Losses) on Derivative Instruments | Foreign Currency Translation Adjustments | Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance as of June 30, 2021 | $ | (6,193 | ) | $ | (51,098 | ) | $ | (57,291 | ) | |||
| Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne | 1,682 | (6,750 | ) | (5,068 | ) | |||||||
| Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1) | 2,884 | $ | - | $ | 2,884 | |||||||
| Balance as of December 31, 2021(2) | $ | (1,626 | ) | (57,848 | ) | (59,474 | ) |
| Unrealized Gains (Losses) on Derivative Instruments | Foreign Currency Translation Adjustments | Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance as of June 30, 2020 attributable to Bio-Techne | $ | (13,253 | ) | $ | (83,946 | ) | $ | (97,199 | ) | |||
| Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne | (47 | ) | 28,759 | 28,712 | ||||||||
| Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne (3) | 4,249 | - | 4,249 | |||||||||
| Balance as of December 31, 2020(2) | $ | (9,051 | ) | $ | (55,187 | ) | $ | (64,238 | ) |
| (1) | Gains (losses) on the interest swap are reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $3,777 to interest expense and a related tax benefit of $892 during the six months ended December 31, 2021. |
|---|
| (2) | The Company had net deferred tax benefits of $502 and $2,886 included in the accumulated other comprehensive income loss as of December 31, 2021 and 2020, respectively. |
|---|
| (3) | Gains (losses) on the interest swap are reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $5,026 to interest expense and $512 to non-operating income relating to variable interest payments that were probable not to occur in the six months ended December 31, 2020. The Company also recorded a related tax benefit of $1,289 during the six months ended December 31, 2020. |
|---|
_Note _9.__ Earnings Per Share:
The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts):
| Quarter Ended | Six Months Ended | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| December 31, | December 31, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Earnings per share – basic: | ||||||||||||||||
| Net earnings, including noncontrolling interest | $ | 72,059 | $ | 46,144 | $ | 141,040 | $ | 79,538 | ||||||||
| Less net earnings (loss) attributable to noncontrolling interest | (8,114 | ) | (130 | ) | (8,748 | ) | (130 | ) | ||||||||
| Net earnings attributable to Bio-Techne | $ | 80,173 | $ | 46,274 | $ | 149,788 | $ | 79,668 | ||||||||
| Income allocated to participating securities | (34 | ) | (37 | ) | (70 | ) | (50 | ) | ||||||||
| Income available to common shareholders | $ | 80,139 | $ | 46,237 | $ | 149,718 | $ | 79,618 | ||||||||
| Weighted-average shares outstanding – basic | 39,310 | 38,691 | 39,202 | 38,614 | ||||||||||||
| Earnings per share – basic | $ | 2.04 | $ | 1.20 | $ | 3.82 | $ | 2.06 | ||||||||
| Earnings per share – diluted: | ||||||||||||||||
| Net earnings, including noncontrolling interest | $ | 72,059 | $ | 46,144 | $ | 141,040 | $ | 79,538 | ||||||||
| Less net earnings (loss) attributable to noncontrolling interest | (8,114 | ) | (130 | ) | (8,748 | ) | (130 | ) | ||||||||
| Net earnings attributable to Bio-Techne | $ | 80,173 | $ | 46,274 | $ | 149,788 | $ | 79,668 | ||||||||
| Income allocated to participating securities | (34 | ) | (37 | ) | (70 | ) | (50 | ) | ||||||||
| Income available to common shareholders | $ | 80,139 | $ | 46,237 | $ | 149,718 | $ | 79,618 | ||||||||
| Weighted-average shares outstanding – basic | 39,310 | 38,691 | 39,202 | 38,614 | ||||||||||||
| Dilutive effect of stock options and restricted stock units | 1,897 | 1,566 | 1,957 | 1,521 | ||||||||||||
| Weighted-average common shares outstanding – diluted | 41,207 | 40,257 | 41,159 | 40,135 | ||||||||||||
| Earnings per share – diluted | $ | 1.94 | $ | 1.15 | $ | 3.64 | $ | 1.98 |
The dilutive effect of stock options and restricted stock units in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 0.7 million and 1.6 million for the quarter ended December 31, 2021 and 2020, respectively and 0.5 million and 1.5 million for the six months ended December 31, 2021 and 2020 respectively.
Note 10. Share-based Compensation:
During the six months ended December 31, 2021 and 2020, the Company granted 0.3 million and 0.7 million stock options at weighted average grant prices of $483.48 and $267.59 and weighted average fair values of $119.27 and $56.88, respectively. During the six months ended December 31, 2021 and 2020, the Company granted 21,218 and 22,367 restricted stock units at a weighted average fair value of $485.94 and $267.87, respectively. During the six months ended December 31, 2021 and 2020, the Company granted 6,896 and 11,803 shares of restricted common stock shares at a weighted average fair value of $489.34 and $264.73.
Stock options for 470,942 and 293,262 shares of common stock with total intrinsic values of $170.7 million and $50.6 million were exercised during the six months ended December 31, 2021 and 2020, respectively.
Stock-based compensation expense, inclusive of payroll taxes, of $14.1 million and $15.6 million was included in selling, general and administrative expenses for the quarter ended December 31, 2021 and 2020, respectively. Stock-based compensation expenses, inclusive of payroll taxes, of $27.3 million and $28.5 million was included in selling, general, and administrative expenses for the six months ended December 31, 2021 and 2020, respectively. Additionally, the company recognized $0.4 million and $0.8 million of stock-based compensation costs in cost of goods sold in the quarter and six months ended December 31, 2021 respectively, compared to $0.6 million and $1 million in cost of goods sold in the comparative prior year periods. As of December 31, 2021, there was $54.1 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock. The weighted average period over which the compensation cost is expected to be recognized is 2.2 years.
In fiscal 2015, the Company established the Bio-Techne Corporation 2014 Employee Stock Purchase Plan (ESPP), which was approved by the Company's shareholders on October 30, 2014, and which is designed to comply with IRS provisions governing employee stock purchase plans. 200,000 shares were allocated to the ESPP. The Company recorded expense of $0.3 million and $0.1 million for the ESPP for the quarter ended December 31, 2021 and 2020, respectively. The Company recorded expense of $0.6 million and $0.4 million for the ESPP for the six months ended December 31, 2021 and 2020, respectively.
Note 11. Other Income / (Expense):
The components of other income (expense) in the accompanying Statement of Earnings and Comprehensive Income are as follows:
| Quarter Ended | Six Months | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| December 31, | December 31, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Interest expense | $ | (2,902 | ) | $ | (3,585 | ) | $ | (6,311 | ) | $ | (8,002 | ) | ||||
| Interest income | 245 | 78 | 438 | 192 | ||||||||||||
| Other non-operating income (expense), net(1) | 26,488 | 8,880 | 33,865 | 3,429 | ||||||||||||
| Total other income (expense) | $ | 23,831 | $ | 5,373 | $ | 27,992 | $ | (4,381 | ) |
| (1) | Primarily due to a $28.4 million and $33.7 million gain in the fair value of our CCXI investment for the quarter and six months ended December 31, 2021, respectively, as compared to a $10.7 million and $6.4 million gain in the comparative periods. |
|---|
Note 12. Income Taxes:
The Company’s effective income tax rate for the second quarter of fiscal 2022 and 2021 was 16.4% and 18.1% of consolidated earnings before income taxes, and 8.2% and 16.9% for the first six months of fiscal 2022 and 2021, respectively. The change in the company’s tax rate for the quarter and six months ended December 31, 2021 compared to the quarter and six months ended December 3__1, 2020 was driven by discrete tax items.
The Company recognized total net benefits related to discrete tax items of $7.6 million and $25.3 million during the quarter and six months ended December 31, 2021, respectively, compared to $3.7 million and $7.8 million during the quarter and six months ended December 31, 2020, respectively. Share-based compensation excess tax benefit contributed $6.1 million and $24.4 million in the quarter and six months ended December 31, 2021, respectively, compared to $4.8 million and $8.0 million in the quarter and six months, ended December 31, 2020, respectively. The Company recognized total other immaterial net discrete tax benefit of $1.5 million and $0.9 million in the quarter and six months ended December 31, 2021, respectively, compared to $1.1 million and $0.2 million of other immaterial net discrete tax expense in the quarter and six months ended December 31, 2020, respectively.
Note 13. Segment Information:
The Company's management evaluates segment operating performance based on operating income before certain charges to cost of sales and selling, general and administrative expenses, principally associated with the impact of partially owned consolidated subsidiaries as well as acquisition accounting related to inventory, amortization of acquisition-related intangible assets and other acquisition-related expenses. The Protein Sciences and Diagnostics and Genomics segments both include consumables, instruments, services and royalty revenue.
The following is financial information relating to the Company's reportable segments (in thousands):
| Quarter Ended | Six Months Ended | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| December 31, | December 31, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Net sales: | ||||||||||||||||
| Protein Sciences | $ | 204,971 | $ | 172,179 | $ | 402,156 | $ | 326,625 | ||||||||
| Diagnostics and Genomics | 64,527 | 52,469 | 125,512 | 102,595 | ||||||||||||
| Intersegment | (222 | ) | (395 | ) | (673 | ) | (768 | ) | ||||||||
| Consolidated net sales | $ | 269,276 | $ | 224,253 | $ | 526,995 | $ | 428,452 | ||||||||
| Operating income: | ||||||||||||||||
| Protein Sciences | $ | 93,281 | $ | 80,453 | $ | 183,381 | $ | 150,803 | ||||||||
| Diagnostics and Genomics | 10,880 | 8,107 | 18,344 | 16,781 | ||||||||||||
| Segment operating income | $ | 104,161 | $ | 88,560 | $ | 201,725 | $ | 167,584 | ||||||||
| Costs recognized on sale of acquired inventory | (84 | ) | (23 | ) | (1,595 | ) | (23 | ) | ||||||||
| Amortization of acquisition related intangible assets | (18,380 | ) | (15,027 | ) | (36,769 | ) | (30,528 | ) | ||||||||
| Impact of partially owned consolidated subsidiaries(1) | (1,004 | ) | (207 | ) | (2,567 | ) | (207 | ) | ||||||||
| Acquisition related expenses | 13,262 | (4,421 | ) | 15,618 | (4,558 | ) | ||||||||||
| Eminence impairment | (18,715 | ) | - | (18,715 | ) | - | ||||||||||
| Stock based compensation, inclusive of employer taxes | (14,815 | ) | (16,225 | ) | (28,675 | ) | (29,557 | ) | ||||||||
| Restructuring costs | (743 | ) | (142 | ) | (1,928 | ) | (142 | ) | ||||||||
| Corporate general, selling, and administrative expenses | (1,334 | ) | (1,520 | ) | (1,524 | ) | (2,482 | ) | ||||||||
| Consolidated operating income | $ | 62,348 | $ | 50,995 | $ | 125,570 | $ | 100,087 |
(1) Adjusted operating income for the second quarter and full year of fiscal 2021 have been updated for comparability to fiscal 2022 for the inclusion of the impact of partially owned consolidated subsidiaries on the Company’s adjusted operating income.
Note 14. Subsequent Events:
None.
16
Previous: Cover and table of contents · Next: Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL